OTC · Biotechnology

Biotest AG (BTTAY) Stock

$24.21 -0.10% OTC: BTTAY Healthcare

Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines.

Valuation

MetricValue
Price$24.21
Market Cap$1.88B
P/E Ratio48.06
P/B Ratio2.40
P/S Ratio2.18
EPS (TTM)$0.50
52-Week High$24.27
52-Week Low$22.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE5.13%
ROA1.84%
ROCE7.42%
Gross Margin30.82%
Operating Margin13.01%
Net Margin3.64%
Debt/Equity1.13
Current Ratio5.06

Annual Financials (USD)

Metric20202021202220232024
Revenue$484.0M$516.0M$516.0M$685.0M$726.0M
Operating Profit$-1.0M$-47.0M$-17.0M$144.0M$95.0M
Net Profit$-31.0M$-63.0M$-32.0M$127.0M$26.0M
EPS$-0.39$-0.80$-0.40$1.60$0.36
Op Margin-0.3%-9.1%-3.2%21.0%13.0%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$1.1B$1.1B$1.2B$1.4B$1.4B
Total Liabilities$690.0M$724.0M$832.0M$912.0M$903.0M
Cash$71.0M$104.0M$117.0M$119.0M$108.0M
Borrowings$469.0M$496.0M$574.0M$690.0M$597.0M

Latest News

Did Analyst Upgrades and Buybacks Just Shift Newmont's (NEM) Operational Efficiency Investment Narrative? Simply Wall St. · Jul 16, 2026 Hu Jiaqi Welcomes Nobel Laureate Eric Maskin as Special Advisor to Humanitas Ark GlobeNewswire · Jul 16, 2026 How Investors Are Reacting To Sterling Infrastructure (STRL) Expanding Its US$1.5 Billion Credit Facility Simply Wall St. · Jul 16, 2026 Csquare (CSQR) Prices Its IPO At $21.00, Is A 3.2x P S Multiple Too Rich? Simply Wall St. · Jul 16, 2026 StubHub Holdings (STUB) Earnings Are Coming As Its Fair Value Story Faces A Test Simply Wall St. · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-17.0M$34.0M$-40.0M$-3.0M$61.0M
Investing Cash Flow$-42.0M$-42.0M$-66.0M$-32.0M$-54.0M
Financing Cash Flow$-5.0M$-2.0M$-10.0M$-5.0M$-6.0M
Net Cash Flow$11.0M$33.0M$12.0M$-8.0M$0
Free Cash Flow$-44.0M$16.0M$-70.0M$-36.0M$32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.42
EV / EBITDA17.22
FCF Yield2.03%
Quick Ratio2.06
Interest Coverage2.97
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CKDXFCeryvyn Therapeutics Limited $0.01 +0.00% 0.06 $13.68M 0.00%
CLAZFClaritas Pharmaceuticals, Inc. $0.00 — 0.00 $3659 0.00%
CSWYFChina Shineway Pharmaceutical Group Limited $1.00 +0.00% 5.76 $758.42M 12.00%
EBRCZEBR Systems, Inc. $0.27 +0.00% -2.82 $172.39M 0.00%
IVEVFInventiva S.A. $3.59 +0.00% -2.04 $499.23M 0.00%

About Biotest AG

Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines. The company's operations are structured across its Therapy, Plasma & Services, and Other divisions. Biotest's product portfolio addresses critical needs within hematology, clinical immunology, and intensive care medicine. For instance, Biotest provides treatments for hemophilia, including Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Its infectious disease portfolio features therapies like Cytotect CP for cytomegalovirus, Varitect for varicella zoster virus, and several Hepatitis B-related products such as Fovepta (for neonate prophylaxis), Hepatect (reinfection prophylaxis), and Zutectra (post-liver transplant reinfection prevention). For immune system disorders and certain neurological conditions, Biotest offers Intratect and IgG Next Generation, targeting primary and secondary antibody deficiencies, and autoimmune diseases. Additionally, Biotest produces Albiomin and Biseko for plasma volume restoration, alongside Cofact and Fibrinogen to address various clotting factor deficiencies, including congenital fibrinogen deficiency. Specialized treatments further comprise Trimodulin for community-acquired pneumonia and COVID-19, and Pentaglobin for bacterial infections. Initially established as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. As of January 21, 2022, Biotest AG functions as a subsidiary of Grifols, S.A.

Biotest AG is headquartered in DE.

Biotest AG (BTTAY) stock trades at $24.21 with a market capitalization of $1.88B. The stock is valued at a price-to-earnings (P/E) ratio of 48.06, price-to-book of 2.40, price-to-sales of 2.18. Over the past 52 weeks the stock has ranged between $22.80 and $24.27, and currently trades at its 52-week high.

On profitability, Biotest AG generates a return on equity (ROE) of 5.13%, return on capital employed of 7.42%, an operating margin of 13.01%, a net profit margin of 3.64%.

Official website: www.biotest.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides